NeoGenomics (NEO) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NeoGenomics Reports 18% Revenue Growth and Strong Gains in Adjusted EBITDA
July 23, 2015 7:01 AM EDTFT. MYERS, Fla., July 23, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015.
Second Quarter 2015 Highlights:
18% increase in consolidated revenue 9% growth in base(1) revenue despite $2.1 million reduction in FISH reimbursement 21% growth in base(1) test volume despite FISH insourcing by one large client Record low $215 Avg Cost per Test in base(1) business 300 basis point expansion in gross margin from 41.4% in... More